We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $0.04 | — | — | $222.2M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.17 | — | — | $157.21M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $0.98 | — | — | $493.15M |
Consensus PT $88 · 5 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 28. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $0.57 | — | — | $310.6M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 945,884 | $38.13B | 0.03% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 56,181 | $2.26B | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Stored first · Google News · Yahoo Finance (English)
Corcept Therapeutics (CORT) Is Up 15.4% After Positive Lifyorli Phase 3 Ovarian Cancer Survival Data – Has The Bull Case Changed? - simplywall.st
Corcept Therapeutics (CORT) Is Up 15.4% After Positive Lifyorli Phase 3 Ovarian Cancer Survival Data – Has The Bull Case Changed? simplywall.st
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak - Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak - Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak Trefis
Corcept Therapeutics chief accounting officer sells $325,000 in stock - Investing.com
Corcept Therapeutics chief accounting officer sells $325,000 in stock Investing.com
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity Stock Titan